Toll Free: 1-888-928-9744

EMEA (Europe, Middle East and Africa) High Potency Active Pharmaceutical Ingredients (HPAPI) Industry 2017 Market Research Report

Published: Nov 6, 2017 | Pages: 114 | Publisher: QYResearch | Industry: Pharmaceutical | Report Format: Electronic (PDF)

In this report, the EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of High Potency Active Pharmaceutical Ingredients (HPAPI) for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) market competition by top manufacturers/players, with High Potency Active Pharmaceutical Ingredients (HPAPI) sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Eli Lilly and Company
    Novartis International AG
    Bristol-Myers Squibb Company
    Roche Diagnostics Limited
    Sanofi Aventis
    Hospira, Inc.
    BASF AG
    Covidien Plc
    Boehringer Ingelheim GmbH
    Merck & Co., Inc.
    Sigma Aldrich Corporation
    Bayer AG
    Carbogen Amcis AG
    Lonza
    Teva Pharmaceuticals Industries Ltd.

On the basis of product, this report displays the sales volume (K Units), revenue (Million USD), product price (USD/Unit), market share and growth rate of each type, primarily split into
    Synthetic
    Biotech

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Units), market share and growth rate of High Potency Active Pharmaceutical Ingredients (HPAPI) for each application, including
    Oncology
    Hormonal
    Glaucoma
    Others

If you have any special requirements, please let us know and we will offer you the report as you want.

 Table of Contents

EMEA (Europe, Middle East and Africa) High Potency Active Pharmaceutical Ingredients (HPAPI) Market Report 2017
1 High Potency Active Pharmaceutical Ingredients (HPAPI) Overview
    1.1 Product Overview and Scope of High Potency Active Pharmaceutical Ingredients (HPAPI)
    1.2 Classification of High Potency Active Pharmaceutical Ingredients (HPAPI)
        1.2.1 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Synthetic
        1.2.4 Biotech
    1.3 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market by Application/End Users
        1.3.1 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Oncology
        1.3.3 Hormonal
        1.3.4 Glaucoma
        1.3.5 Others
    1.4 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market by Region
        1.4.1 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of High Potency Active Pharmaceutical Ingredients (HPAPI) (2012-2022)
        1.5.1 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2022)
        1.5.2 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue and Growth Rate (2012-2022)

2 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market Competition by Players/Manufacturers
        2.1.1 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue and Share by Players (2012-2017)
        2.1.3 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sale Price by Players (2012-2017)
    2.2 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) (Volume and Value) by Type/Product Category
        2.2.1 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sale Price by Type (2012-2017)
    2.3 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) (Volume) by Application
    2.4 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) (Volume and Value) by Region
        2.4.1 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Price by Region (2012-2017)

3 Europe High Potency Active Pharmaceutical Ingredients (HPAPI) (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Value (2012-2017)
        3.1.1 Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue and Growth Rate (2012-2017)
    3.2 Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Market Share by Type
    3.3 Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Market Share by Application
    3.4 Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume by Countries (2012-2017)
        3.4.2 Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue by Countries (2012-2017)
        3.4.3 Germany High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2017)
        3.4.4 France High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2017)
        3.4.5 UK High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2017)
        3.4.6 Russia High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2017)
        3.4.7 Italy High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2017)
        3.4.8 Benelux High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2017)

4 Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Value (2012-2017)
        4.1.1 Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue and Growth Rate (2012-2017)
    4.2 Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Market Share by Type
    4.3 Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Market Share by Application
    4.4 Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume by Countries (2012-2017)
        4.4.2 Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2017)
        4.4.4 Israel High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2017)
        4.4.5 UAE High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2017)
        4.4.6 Iran High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2017)

5 Africa High Potency Active Pharmaceutical Ingredients (HPAPI) (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Value (2012-2017)
        5.1.1 Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue and Growth Rate (2012-2017)
    5.2 Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Market Share by Type
    5.3 Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Market Share by Application
    5.4 Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume by Countries (2012-2017)
        5.4.2 Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue by Countries (2012-2017)
        5.4.3 South Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2017)
        5.4.5 Egypt High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2017)
        5.4.6 Algeria High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate (2012-2017)

6 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Manufacturers/Players Profiles and Sales Data
    6.1 Eli Lilly and Company
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 High Potency Active Pharmaceutical Ingredients (HPAPI) Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Eli Lilly and Company High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Novartis International AG
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 High Potency Active Pharmaceutical Ingredients (HPAPI) Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Novartis International AG High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Bristol-Myers Squibb Company
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 High Potency Active Pharmaceutical Ingredients (HPAPI) Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Bristol-Myers Squibb Company High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Roche Diagnostics Limited
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 High Potency Active Pharmaceutical Ingredients (HPAPI) Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Roche Diagnostics Limited High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Sanofi Aventis
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 High Potency Active Pharmaceutical Ingredients (HPAPI) Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Sanofi Aventis High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Hospira, Inc.
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 High Potency Active Pharmaceutical Ingredients (HPAPI) Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Hospira, Inc. High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 BASF AG
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 High Potency Active Pharmaceutical Ingredients (HPAPI) Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 BASF AG High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Covidien Plc
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 High Potency Active Pharmaceutical Ingredients (HPAPI) Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Covidien Plc High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Boehringer Ingelheim GmbH
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 High Potency Active Pharmaceutical Ingredients (HPAPI) Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Boehringer Ingelheim GmbH High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Merck & Co., Inc.
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 High Potency Active Pharmaceutical Ingredients (HPAPI) Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Merck & Co., Inc. High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue, Price and Gross Margin (2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Sigma Aldrich Corporation
    6.12 Bayer AG
    6.13 Carbogen Amcis AG
    6.14 Lonza
    6.15 Teva Pharmaceuticals Industries Ltd.

7 High Potency Active Pharmaceutical Ingredients (HPAPI) Manufacturing Cost Analysis
    7.1 High Potency Active Pharmaceutical Ingredients (HPAPI) Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 High Potency Active Pharmaceutical Ingredients (HPAPI) Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of High Potency Active Pharmaceutical Ingredients (HPAPI) Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market Forecast (2017-2022)
    11.1 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Price and Trend Forecast (2017-2022)
    11.2 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Type (2017-2022)
    11.7 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer


List of Tables and Figures

    Figure Product Picture of High Potency Active Pharmaceutical Ingredients (HPAPI)
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume (K Units) by Type (2012-2022)
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume Market Share by Type (Product Category) in 2016
    Figure Synthetic Product Picture
    Figure Biotech Product Picture
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume (K Units) by Application (2012-2022)
    Figure EMEA Sales Market Share of High Potency Active Pharmaceutical Ingredients (HPAPI) by Application in 2016
    Figure Oncology Examples
    Table Key Downstream Customer in Oncology
    Figure Hormonal Examples
    Table Key Downstream Customer in Hormonal
    Figure Glaucoma Examples
    Table Key Downstream Customer in Glaucoma
    Figure Others Examples
    Table Key Downstream Customer in Others
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market Size (Million USD) by Region (2012-2022)
    Figure Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) and Growth Rate (2012-2022)
    Figure Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) Status and Forecast by Countries
    Figure Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) and Growth Rate (2012-2022)
    Figure Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) Status and Forecast by Countries
    Figure Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) and Growth Rate (2012-2022)
    Figure Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) Status and Forecast by Countries
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume and Growth Rate (2012-2022)
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) and Growth Rate (2012-2022)
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market Major Players Product Sales Volume (K Units) (2012-2017)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume (K Units) of Major Players (2012-2017)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Share by Players (2012-2017)
    Figure 2016 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Share by Players
    Figure 2017 High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Share by Players
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Market Major Players Product Revenue (Million USD) (2012-2017)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) by Players (2012-2017)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Share by Players (2012-2017)
    Table 2016 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Share by Players
    Table 2017 EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Share by Players
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sale Price (USD/Unit) by Players (2012-2017)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Market Share by Type (2012-2017)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Share by Type (2012-2017)
    Figure Sales Market Share of High Potency Active Pharmaceutical Ingredients (HPAPI) by Type (2012-2017)
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Type (2012-2017)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) and Market Share by Type (2012-2017)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Share by Type (2012-2017)
    Figure Revenue Market Share of High Potency Active Pharmaceutical Ingredients (HPAPI) by Type in 2016
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sale Price (USD/Unit) by Type (2012-2017)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Market Share by Application (2012-2017)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Share by Application (2012-2017)
    Figure Sales Market Share of High Potency Active Pharmaceutical Ingredients (HPAPI) by Application (2012-2017)
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Application in 2016
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Market Share by Region (2012-2017)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Share by Region (2012-2017)
    Figure Sales Market Share of High Potency Active Pharmaceutical Ingredients (HPAPI) by Region (2012-2017)
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share in 2016
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) and Market Share by Region (2012-2017)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Share by Region (2012-2017)
    Figure Revenue Market Share of High Potency Active Pharmaceutical Ingredients (HPAPI) by Region (2012-2017)
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share Regions in 2016
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Price (USD/Unit) by Region (2012-2017)
    Figure Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue and Growth Rate (2012-2017)
    Table Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) by Type (2012-2017)
    Table Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Share by Type (2012-2017)
    Figure Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Share by Type in 2016
    Table Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) by Application (2012-2017)
    Table Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Share by Application (2012-2017)
    Figure Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Market Share by Application in 2016
    Table Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) by Countries (2012-2017)
    Table Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Countries (2012-2017)
    Figure Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Countries (2012-2017)
    Figure Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Countries in 2016
    Table Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) by Countries (2012-2017)
    Table Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Countries (2012-2017)
    Figure Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Countries (2012-2017)
    Figure Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Countries in 2016
    Figure Germany High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure France High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure UK High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Russia High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Italy High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Benelux High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) and Growth Rate (2012-2017)
    Table Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) by Type (2012-2017)
    Table Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Market Share by Type (2012-2017)
    Figure Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Market Share by Type (2012-2017)
    Table Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) by Applications (2012-2017)
    Table Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Market Share by Applications (2012-2017)
    Figure Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Application in 2016
    Table Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume (K Units) by Countries (2012-2017)
    Table Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume Market Share by Countries (2012-2017)
    Figure Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume Market Share by Countries in 2016
    Table Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) by Countries (2012-2017)
    Table Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Countries (2012-2017)
    Figure Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Countries (2012-2017)
    Figure Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Countries in 2016
    Figure Saudi Arabia High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Israel High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure UAE High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Iran High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) and Growth Rate (2012-2017)
    Table Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) by Type (2012-2017)
    Table Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Type (2012-2017)
    Figure Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Type (2012-2017)
    Figure Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Type in 2016
    Table Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) by Application (2012-2017)
    Table Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Application (2012-2017)
    Figure Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Application (2012-2017)
    Table Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Volume (K Units) by Countries (2012-2017)
    Table Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Countries (2012-2017)
    Figure Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Countries (2012-2017)
    Figure Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share by Countries in 2016
    Table Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) by Countries (2012-2017)
    Table Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Countries (2012-2017)
    Figure Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Countries (2012-2017)
    Figure Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share by Countries in 2016
    Figure South Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Nigeria High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Egypt High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Algeria High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Table Eli Lilly and Company High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table Eli Lilly and Company High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
    Figure Eli Lilly and Company High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Eli Lilly and Company High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share in EMEA (2012-2017)
    Figure Eli Lilly and Company High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share in EMEA (2012-2017)
    Table Novartis International AG High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table Novartis International AG High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
    Figure Novartis International AG High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Novartis International AG High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share in EMEA (2012-2017)
    Figure Novartis International AG High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share in EMEA (2012-2017)
    Table Bristol-Myers Squibb Company High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table Bristol-Myers Squibb Company High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
    Figure Bristol-Myers Squibb Company High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Bristol-Myers Squibb Company High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share in EMEA (2012-2017)
    Figure Bristol-Myers Squibb Company High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share in EMEA (2012-2017)
    Table Roche Diagnostics Limited High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table Roche Diagnostics Limited High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
    Figure Roche Diagnostics Limited High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Roche Diagnostics Limited High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share in EMEA (2012-2017)
    Figure Roche Diagnostics Limited High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share in EMEA (2012-2017)
    Table Sanofi Aventis High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table Sanofi Aventis High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
    Figure Sanofi Aventis High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Sanofi Aventis High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share in EMEA (2012-2017)
    Figure Sanofi Aventis High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share in EMEA (2012-2017)
    Table Hospira, Inc. High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table Hospira, Inc. High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
    Figure Hospira, Inc. High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Hospira, Inc. High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share in EMEA (2012-2017)
    Figure Hospira, Inc. High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share in EMEA (2012-2017)
    Table BASF AG High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table BASF AG High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
    Figure BASF AG High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure BASF AG High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share in EMEA (2012-2017)
    Figure BASF AG High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share in EMEA (2012-2017)
    Table Covidien Plc High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table Covidien Plc High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
    Figure Covidien Plc High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Covidien Plc High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share in EMEA (2012-2017)
    Figure Covidien Plc High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share in EMEA (2012-2017)
    Table Boehringer Ingelheim GmbH High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table Boehringer Ingelheim GmbH High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
    Figure Boehringer Ingelheim GmbH High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Boehringer Ingelheim GmbH High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share in EMEA (2012-2017)
    Figure Boehringer Ingelheim GmbH High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share in EMEA (2012-2017)
    Table Merck & Co., Inc. High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table Merck & Co., Inc. High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
    Figure Merck & Co., Inc. High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate (2012-2017)
    Figure Merck & Co., Inc. High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share in EMEA (2012-2017)
    Figure Merck & Co., Inc. High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share in EMEA (2012-2017)
    Table Sigma Aldrich Corporation High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table Bayer AG High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table Carbogen Amcis AG High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table Lonza High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table Teva Pharmaceuticals Industries Ltd. High Potency Active Pharmaceutical Ingredients (HPAPI) Basic Information List
    Table Production Base and Market Concentration Rate of Raw Material
    Figure Price Trend of Key Raw Materials
    Table Key Suppliers of Raw Materials
    Figure Manufacturing Cost Structure of High Potency Active Pharmaceutical Ingredients (HPAPI)
    Figure Manufacturing Process Analysis of High Potency Active Pharmaceutical Ingredients (HPAPI)
    Figure High Potency Active Pharmaceutical Ingredients (HPAPI) Industrial Chain Analysis
    Table Raw Materials Sources of High Potency Active Pharmaceutical Ingredients (HPAPI) Major Manufacturers in 2016
    Table Major Buyers of High Potency Active Pharmaceutical Ingredients (HPAPI)
    Table Distributors/Traders List
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) and Growth Rate Forecast (2017-2022)
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue and Growth Rate Forecast (2017-2022)
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Price (USD/Unit) and Trend Forecast (2017-2022)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) Forecast by Region (2017-2022)
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share Forecast by Region (2017-2022)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) Forecast by Region (2017-2022)
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share Forecast by Region (2017-2022)
    Table Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) Forecast by Countries (2017-2022)
    Figure Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share Forecast by Countries (2017-2022)
    Table Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) Forecast by Countries (2017-2022)
    Figure Europe High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share Forecast by Countries (2017-2022)
    Table Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) Forecast by Countries (2017-2022)
    Figure Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share Forecast by Countries (2017-2022)
    Table Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) Forecast by Countries (2017-2022)
    Figure Middle East High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share Forecast by Countries (2017-2022)
    Table Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) Forecast by Countries (2017-2022)
    Figure Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share Forecast by Countries (2017-2022)
    Table Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue (Million USD) Forecast by Countries (2017-2022)
    Figure Africa High Potency Active Pharmaceutical Ingredients (HPAPI) Revenue Market Share Forecast by Countries (2017-2022)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) Forecast by Type (2017-2022)
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share Forecast by Type (2017-2022)
    Table EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales (K Units) Forecast by Application (2017-2022)
    Figure EMEA High Potency Active Pharmaceutical Ingredients (HPAPI) Sales Market Share Forecast by Application (2017-2022)
    Table Research Programs/Design for This Report
    Figure Bottom-up and Top-down Approaches for This Report
    Figure Data Triangulation
    Table Key Data Information from Secondary Sources
    Table Key Data Information from Primary Sources

 



To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmen

Read More...

Global compressed air treatment equipment market is projected to reach USD 8.59 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing implementation of this equipment in various industry sectors such as healthcare & pharmace

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...

Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expected

Read More...

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...
Choose License Type
Single User - US $4000
Multi User - US $8000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify